证券代码：300314 证券简称：戴维医疗 公告编号：2025-088 宁波戴维医疗器械股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得由 浙江省药品监督管理局颁发的1项《医疗器械注册证》，公司产品多参数 监护仪完成了延续注册，具体如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期至 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 1 | 多参数监护仪 | 浙械注准 | 2031.6.2 | Ⅱ类 | 用于医疗机构对患者进行心 | | | | 20212070235 | | | 电（ECG）、心率（HR）、呼 | | | | | | | 吸 （ Resp ） 、 血 氧 饱 和 度 | | | | | | | （SpO2）、脉率（PR）、无创 | | | | | | | 血压（NIBP）、体温（Temp）、 | | | | | | | 二氧化碳（CO2）生理参数的 | | | | | | | 监测。 | 本次延续 ...

证券日报网讯12月12日，戴维医疗（300314）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东总户数约为19300户。 ...

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

格隆汇12月10日丨戴维医疗(300314.SZ)公布，新产品电动手术台获得了浙江省药品监督管理局颁发的 《医疗器械注册证》，电动手术台是手术治疗中不可缺少的基础医疗设备，主要用于支撑患者身体、调 整手术体位、充分暴露手术野，使医护人员在方便、舒适的条件下顺利完成各类手术。其核心价值是在 于是否安全舒适、好用且耐用。公司本次获注册的电动手术台，采用电动液压控制方式，通过微型按键 开关控制器灵活控制台面的各种运动，以满足手术所需的各种体位要求。可在任何体位下都具有高承重 的功能，能够满足手术的多变性和患者的不同体位。模块化设计的台面更能适用于多种多样的手术，简 单的按钮式连接关节使其操作更加简便。 ...

南财智讯12月10日电，戴维医疗公告，公司收到浙江省药品监督管理局颁发的《医疗器械注册证》，产 品名称为电动手术台，型号规格包括DT-100/DT-100A/DT-100B/DT-100C/DT-100D，注册分类为Ⅱ类， 有效期至2030年12月7日。适用范围为常规手术、神经外科、胸腹外科、骨科、泌尿外科肛肠科、整形 外科、妇科、肝胆外科及普外科手术等医疗过程的患者多体位支撑与操作。以上产品医疗器械注册证的 取得，有利于丰富公司产品线，进一步提高公司的核心竞争力，对公司未来的经营成果将产生积极影 响。目前尚无法预测该等产品对公司未来营业收入的影响，敬请投资者注意投资风险。 ...

戴维医疗12月10日公告，公司电动手术台获得浙江省药品监督管理局颁发的《医疗器械注册证》。本设 备用于常规手术、神经外科、胸腹外科、骨科、泌尿外科肛肠科、整形外科、妇科，肝胆外科及普外科 手术等医疗过程的患者 多体位支撑与操作，使其躺卧成不同的姿势。以上产品医疗器械注册证的取 得，有利于丰富公司产品线，进一步提高公司的核心竞争力，对公司未来的经营成果将产生积极影响。 目前尚无法预测该等产品对公司未来营业收入的影响。 ...

戴维医疗（300314）(300314.SZ)公告，公司新产品电动手术台获得了浙江省药品监督管理局颁发的 《医疗器械注册证》。 ...

智通财经APP讯，戴维医疗(300314.SZ)公告，公司新产品电动手术台获得了浙江省药品监督管理局颁发 的《医疗器械注册证》。 ...

产品名称：电动手术台 型号、规格：DT-100/DT-100A/DT-100B/DT-100C/DT-100D 注册证编号：浙械注准20252151942 证券代码：300314 证券简称：戴维医疗 公告编号：2025-087 宁波戴维医疗器械股份有限公司 关于新产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，宁波戴维医疗器械股份有限公司（以下简称"公司"）的新产 品电动手术台获得了浙江省药品监督管理局颁发的《医疗器械注册证》， 具体如下： 一、医疗器械注册证的具体情况 在任何体位下都具有高承重的功能，能够满足手术的多变性和患者的不同 体位。模块化设计的台面更能适用于多种多样的手术，简单的按钮式连接 关节使其操作更加简便。 三、对公司的影响 以上产品医疗器械注册证的取得，有利于丰富公司产品线，进一步提 高公司的核心竞争力，对公司未来的经营成果将产生积极影响。 批准日期：2025年12月8日 有效期至：2030年12月7日 注册分类：Ⅱ类 适用范围：本设备用于常规手术、神经外科、胸腹外科、骨科、泌尿 外科肛肠科、整形外科、妇科 ...

Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]